Why It Matters

Regeneron Pharmaceuticals is fighting a multi-front regulatory battle threatening its core business model. Congress is pushing bipartisan patent reform to block "pay-for-delay" settlements and "product hopping" that extend drug monopolies, while the Trump administration weaponizes tariffs on imported pharmaceuticals to force domestic manufacturing and lower prices.

The company’s lobbying directly targets these threats—seeking to block reform legislation or negotiate favorable treatment. At stake is whether Regeneron can preserve patent exclusivity periods and pricing power that drive innovation investment, or face a new regime featuring international reference pricing, faster generic competition, and tariff-driven production shifts.

By the Numbers

Regeneron Pharmaceuticals Inc. reported $570,000 in Q3 2025 in-house lobbying expenditures. Since 2016, the company has spent $11.82 million on internal government affairs while engaging external firms including Venn Strategies LLC ($3.2 million, 2013-2022) and Crane Strategies LLC ($1.33 million, 2019-2025).

The company added three new external firms in 2025: BGR Government Affairs LLC for manufacturing policy, Washington Tax and Public Policy Group LLC for corporate tax issues, and Checkmate Government Relations LLC for HHS engagement.

The three-person in-house team features Maddie Davidson with Senate HELP Committee and Finance Committee experience, Katherine Moffitt Haddad from House Energy and Commerce, and Eben DuRoss, formerly with PhRMA.

The Agenda

Regeneron is lobbying on interconnected issues critical to its business model.

Targets include drug pricing policies, intellectual property protection, healthcare regulation, taxation, and trade policy. Most significantly, Regeneron opposes congressional efforts to reform pharmaceutical patent laws—including bans on "pay-for-delay" settlements and "patent thickets"—while navigating Trump administration tariff threats. The company also lobbies on FDA budget issues, Medicare/Medicaid reimbursement, and biodefense appropriations. These priorities have remained consistent across all 38 in-house disclosures since 2013.

Broader Context

Regeneron faces extraordinary policy turbulence in Q3 2025. The Trump administration announced tariffs on branded pharmaceuticals while offering exemptions to companies expanding domestic manufacturing. Congress intensified patent reform efforts, with the Senate Judiciary Committee advancing six bipartisan bills targeting monopoly-extending strategies. Studies show 74% of new drug patents between 2005-2015 covered existing medications.

Supply chain vulnerabilities present risks and opportunities. Congressional hearings revealed bipartisan alarm over Chinese and Indian supplier dependence, potentially benefiting companies with existing U.S. manufacturing like Regeneron. The Medicare drug price negotiation program continues evolving while FDA faces potential budget cuts that could slow reviews.

Between The Lines

Congress is launching a multi-pronged assault on pharmaceutical business models. The Senate Judiciary Committee advanced six bipartisan bills targeting patent abuse practices. Identical bills S.1818 and H.R.3546 would establish international price benchmarking. The Trump administration added 100% tariffs on imported branded drugs unless companies build U.S. manufacturing capacity. This convergence creates an unusually hostile environment for innovator pharmaceutical companies.

Competitive Landscape

Biogen and Novartis lobby on similar issues—drug pricing, patient affordability, PBM reform, and intellectual property protections. The industry’s primary trade group, PhRMA, serves as unified opposition to international reference pricing and patent law changes. The collective effort reflects existential stakes as Congress and the administration pursue aggressive pricing reductions and reform.

The Bottom Line

Regeneron spent $570,000 on in-house lobbying in Q3 2025 amid converging pharmaceutical policy pressures. The company faces Trump tariff threats, bipartisan congressional patent reform, and Medicare price negotiation expansions. However, Regeneron benefits from congressional manufacturing vulnerability concerns—having announced multibillion-dollar domestic investments positioning it favorably for tariff negotiations. This represents standard industry response to an unusually turbulent policy moment rather than extraordinary advocacy intensity.

Spot something wrong? Report an issue with this article